Trials / Recruiting
RecruitingNCT06774963
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 145 (estimated)
- Sponsor
- NextCure, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.
Conditions
- Ovarian Cancer
- Breast Cancer
- Endometrial Cancer
- Biliary Tract Cancer
- Non-Small Cell Lung Cancer
- Advanced or Metastatic Solid Tumors
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LNCB74 | LNCB74 is an antibody drug conjugate being evaluated as a potential treatment for participants with advanced solid tumors. Participants will receive LNCB74 into the vein (IV; intravenously) in 21-day dosing cycles. Participants will continue treatment in the absence of unacceptable toxicities and unequivocal disease progression. |
Timeline
- Start date
- 2025-01-07
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2025-01-14
- Last updated
- 2025-12-16
Locations
14 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06774963. Inclusion in this directory is not an endorsement.